|
1
|
Chapoval AI, Ni J, Lau JS, et al: B7-H3: a
costimulatory molecule for T cell activation and IFN-gamma
production. Nat Immunol. 2:2692001.
|
|
2
|
Dong H, Strome SE, Salomao DR, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002.
|
|
3
|
Hashiguchi M, Kobori H, Ritprajak P,
Kamimura Y, Kozono H and Azuma M: Triggering receptor expressed on
myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for
B7-H3 and enhances T cell responses. Proc Natl Acad Sci USA.
105:10495–10500. 2008.
|
|
4
|
Zhang G, Hou J, Shi J, Yu G, Lu B and
Zhang X: Soluble CD276 (B7-H3) is released from monocytes,
dendritic cells and activated T cells and is detectable in normal
human serum. Immunology. 123:538–546. 2008.
|
|
5
|
Sun J, Chen LJ, Zhang GB, et al: Clinical
significance and regulation of the costimulatory molecule B7-H3 in
human colorectal carcinoma. Cancer Immunol Immunother.
59:1163–1171. 2010.
|
|
6
|
Merimsky O, Shoenfeld Y, Chaitchik S,
Yecheskel G and Fishman P: Antigens and antibodies in malignant
melanoma. Tumor Biol. 15:188–202. 1994.
|
|
7
|
Streit M and Detmar M: Angiogenesis,
lymphangiogenesis, and melanoma metastasis. Oncogene. 22:3172–3179.
2003.
|
|
8
|
Miller AJ and Mihm MC Jr: Melanoma. N Engl
J Med. 355:51–65. 2006.
|
|
9
|
Chen YW, Tekle C and Fodstad O: The
immunoregulatory protein human B7H3 is a tumor-associated antigen
that regulates tumor cell migration and invasion. Curr Cancer Drug
Targets. 8:404–413. 2008.
|
|
10
|
Zang X, Sullivan PS, Soslow RA, et al:
Tumor associated endothel expression of B7-H3 predicts survival in
ovarian carcinomas. Mod Pathol. 23:1104–1112. 2010.
|
|
11
|
Sun Y, Wang Y, Zhao J, et al: B7-H3 and
B7-H4 expression in non-small-cell lung cancer. Lung Cancer.
53:143–151. 2006.
|
|
12
|
Wu CP, Jiang JT, Tan M, et al:
Relationship between co-stimulatory molecule B7-H3 expression and
gastric carcinoma histology and prognosis. World J Gastroenterol.
12:457–459. 2006.
|
|
13
|
Roth TJ, Sheinin Y, Lohse CM, et al: B7-H3
ligand expression by prostate cancer: a novel marker of prognosis
and potential target for therapy. Cancer Res. 67:7893–7900.
2007.
|
|
14
|
Yamato I, Sho M, Nomi T, et al: Clinical
importance of B7-H3 expression in human pancreatic cancer. Br J
Cancer. 101:1709–1716. 2009.
|
|
15
|
Loos M, Hedderich DM, Ottenhausen M, et
al: Expression of the costimulatory molecule B7-H3 is associated
with prolonged survival in human pancreatic cancer. BMC Cancer.
9:4632009.
|
|
16
|
Lemke D, Pfenning PN, Sahm F, et al:
Costimulatory protein 4IgB7H3 drives the malignant phenotype of
glioblastoma mediating immune escape and invasiveness. Clin Cancer
Res. 18:105–117. 2012.
|
|
17
|
Suh WK, Gajewska BU, Okada H, et al: The
B7 family member B7-H3 preferentially down-regulates T helper type
1-mediated immune responses. Nat Immunol. 4:899–906. 2003.
|
|
18
|
Luo L, Chapoval AI, Flies DB, et al: B7-H3
enhances tumor immunity in vivo by costimulating rapid clonal
expansion of antigen-specific CD8+ cytolytic T cells. J
Immunol. 173:5445–5450. 2004.
|
|
19
|
Ma L, Luo L, Qiao H, et al: Complete
eradication of hepatocellular carcinomas by combined vasostatin
gene therapy and B7H3-mediated immunotherapy. J Hepatol. 46:98–106.
2007.
|
|
20
|
Geng L, Huang D, Liu J, et al: B7-H1
up-regulated expression in human pancreatic carcinoma tissue
associates with tumor progression. J Cancer Res Clin Oncol.
134:1021–1027. 2008.
|
|
21
|
Loos M, Giese NA, Kleeff J, et al:
Clinical significance and regulation of the costimulatory molecule
B7-H1 in pancreatic cancer. Cancer Lett. 268:98–109. 2008.
|
|
22
|
Boorjian SA, Sheinin Y, Crispen PL, et al:
T-cell coregulatory molecule expression in urothelial cell
carcinoma: clinicopathologic correlations and association with
survival. Clin Cancer Res. 14:4800–4808. 2008.
|
|
23
|
Frigola X, Inman BA, Lohse CM, et al:
Identification of a soluble form of B7-H1 that retains
immunosuppressive activity and is associated with aggressive renal
cell carcinoma. Clin Cancer Res. 17:1915–1923. 2011.
|
|
24
|
Rubin LL and Staddon JM: The cell biology
of the blood-brain barrier. Annu Rev Neurosci. 22:11–28. 1999.
|
|
25
|
Tseng SY, Otsuji M, Gorski K, et al:
B7-DC, a new dendritic cell molecule with potent costimulatory
properties for T cells. J Exp Med. 193:839–846. 2001.
|
|
26
|
Latchman Y, Wood CR, Chernova T, et al:
PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Nat Immunol. 2:261–268. 2001.
|
|
27
|
Yao Y, Tao R, Wang X, Wang Y, Mao Y and
Zhou LF: B7-H1 is correlated with malignancy-grade gliomas but is
not expressed exclusively on tumor stem-like cells. Neuro Oncol.
11:757–766. 2009.
|
|
28
|
Chen X, Zhang G, Li Y, et al: Circulating
B7-H3(CD276) elevations in cerebrospinal fluid and plasma of
children with bacterial meningitis. J Mol Neurosci. 37:86–94.
2009.
|
